CA2637262C - Compositions and methods for treating collagen-mediated diseases - Google Patents

Compositions and methods for treating collagen-mediated diseases Download PDF

Info

Publication number
CA2637262C
CA2637262C CA2637262A CA2637262A CA2637262C CA 2637262 C CA2637262 C CA 2637262C CA 2637262 A CA2637262 A CA 2637262A CA 2637262 A CA2637262 A CA 2637262A CA 2637262 C CA2637262 C CA 2637262C
Authority
CA
Canada
Prior art keywords
collagenase
drug product
fermentation
lane
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2637262A
Other languages
English (en)
French (fr)
Other versions
CA2637262A1 (en
Inventor
Gregory L. Sabatino
Benjamin J. Del Tito, Jr.
Phillip J. Bassett
Hazel A. Tharia
Antony G. Hitchcock
Thomas L. Wegman
Bo Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biospecifics Technologies LLC
Original Assignee
Biospecifics Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biospecifics Technologies LLC filed Critical Biospecifics Technologies LLC
Publication of CA2637262A1 publication Critical patent/CA2637262A1/en
Application granted granted Critical
Publication of CA2637262C publication Critical patent/CA2637262C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2637262A 2006-01-30 2007-01-30 Compositions and methods for treating collagen-mediated diseases Active CA2637262C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US76347006P 2006-01-30 2006-01-30
US60/763,470 2006-01-30
US78413506P 2006-03-20 2006-03-20
US60/784,135 2006-03-20
US11/699,302 2007-01-29
US11/699,302 US7811560B2 (en) 2006-01-30 2007-01-29 Compositions and methods for treating collagen-mediated diseases
PCT/US2007/002654 WO2007089851A2 (en) 2006-01-30 2007-01-30 Compositions and methods for treating collagen-mediated diseases

Publications (2)

Publication Number Publication Date
CA2637262A1 CA2637262A1 (en) 2007-08-09
CA2637262C true CA2637262C (en) 2014-08-19

Family

ID=38328033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2637262A Active CA2637262C (en) 2006-01-30 2007-01-30 Compositions and methods for treating collagen-mediated diseases

Country Status (17)

Country Link
US (16) US7811560B2 (https=)
EP (6) EP3508571B1 (https=)
JP (8) JP5309289B2 (https=)
KR (2) KR20080093142A (https=)
CN (2) CN105999244B (https=)
AU (2) AU2007211313C1 (https=)
BR (1) BRPI0708017A2 (https=)
CA (1) CA2637262C (https=)
DK (2) DK2474321T3 (https=)
ES (3) ES2992881T3 (https=)
HU (2) HUE041764T2 (https=)
IL (6) IL291175B2 (https=)
MX (1) MX2008009756A (https=)
NZ (2) NZ593907A (https=)
PT (2) PT1987141T (https=)
TR (1) TR201903008T4 (https=)
WO (1) WO2007089851A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
ES2388219T3 (es) * 2008-06-02 2012-10-10 F. Hoffmann-La Roche Ag Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
US8236356B2 (en) * 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
EP2403523A1 (en) * 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
ES2385239B1 (es) 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
WO2013011514A1 (en) 2011-07-20 2013-01-24 Mediwound Ltd. Proteolytic extract from bromelain for the treatment of connective tissue disorders
JP2014530873A (ja) * 2011-10-21 2014-11-20 オーキシリウム インターナショナル ホールディングス，インコーポレイテッド Ｅｆｐの治療または低減方法
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
ITPD20120118A1 (it) * 2012-04-18 2013-10-19 Fidia Farmaceutici "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus"
BR112014027347A2 (pt) 2012-05-01 2017-06-27 Proteolease Ltd método para extrair um dente em um sujeito com essa necessidade, método para substituir um dente com um implante dentário e kit para extrair um dente
BR102012013110A2 (pt) 2012-05-31 2014-05-27 Cristalia Prod Quimicos Farm Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
EP3834840B8 (en) * 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
CA2915814A1 (en) * 2013-06-18 2014-12-24 Harrow Ip, Llc Local use of pentoxifylline to treat peyronie's disease
US10383875B2 (en) 2013-06-18 2019-08-20 Harrow Ip, Llc Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US10117892B2 (en) * 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
DE202014105440U1 (de) * 2014-11-12 2016-02-15 Bilz Werkzeugfabrik Gmbh & Co. Kg Werkzeugaufnahme
KR101723168B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
US10303245B2 (en) * 2015-05-04 2019-05-28 Adobe Inc. Methods and devices for detecting and responding to changes in eye conditions during presentation of video on electronic devices
EP4591945A3 (en) 2017-03-01 2026-04-15 Endo Operations Limited Apparatus and method for assessing and treating cellulite
JP7227918B2 (ja) 2017-03-28 2023-02-22 エンド ベンチャーズ リミテッド コラゲナーゼ産生の改良された方法
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
US20240277595A1 (en) 2018-09-18 2024-08-22 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
US20220305094A1 (en) 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
US11872267B2 (en) 2019-10-15 2024-01-16 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
WO2023131588A1 (en) 2022-01-05 2023-07-13 Nordmark Pharma Gmbh Culture medium for cultivating hathewaya histolytica (or clostridium histolyticum) and the production of one or more proteases
CN116102638B (zh) * 2023-01-09 2025-05-16 中国农业科学院农产品加工研究所 基于亲和吸附富集骨胶原蛋白成骨活性肽的方法
WO2026028155A1 (en) 2024-08-01 2026-02-05 Endo Biologics Limited Methods of treating plantar fasciitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61289885A (ja) * 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) * 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
CA2047306A1 (en) * 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) * 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
WO1994000580A1 (en) * 1992-06-22 1994-01-06 Trigen, Inc. Molecular cloning of the genes reponsible for collagenase production from clostridium histolyticum
JP3186881B2 (ja) * 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
CA2189646C (en) * 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CZ280397A3 (cs) * 1995-03-16 1998-04-15 Knoll Aktiengesellschaft Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění
US5989888A (en) * 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
ATE272109T1 (de) * 1996-11-19 2004-08-15 Roche Diagnostics Gmbh Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) * 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
ATE302844T1 (de) * 2001-07-02 2005-09-15 Nordmark Arzneimittel Gmbh & C Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
EP1462519A1 (en) * 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) * 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
US8536315B2 (en) * 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
US7355027B2 (en) * 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
DE602005014117D1 (de) * 2004-07-07 2009-06-04 Lundbeck As Valby H Neues carbamyliertes epo und verfahren zu dessen herstellung
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
CN101107006B (zh) * 2005-01-21 2013-09-11 纽约州立大学研究基金会 治疗黏连性关节囊炎的方法
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases

Also Published As

Publication number Publication date
EP3508571B1 (en) 2024-08-21
EP1987141A4 (en) 2009-11-18
EP2474319A1 (en) 2012-07-11
JP7191152B2 (ja) 2022-12-16
JP2020039371A (ja) 2020-03-19
EP2474321A1 (en) 2012-07-11
ES2729941T3 (es) 2019-11-07
IL245434A0 (en) 2016-06-30
US20110189163A1 (en) 2011-08-04
IL254184B (en) 2019-02-28
MX2008009756A (es) 2008-12-18
US20140004094A1 (en) 2014-01-02
US20110243909A1 (en) 2011-10-06
IL277322A (en) 2020-10-29
JP5309289B2 (ja) 2013-10-09
EP1987141B8 (en) 2019-03-06
EP2474320A1 (en) 2012-07-11
IL245434A (en) 2017-10-31
IL291175A (en) 2022-05-01
CN101400788B (zh) 2016-06-29
US20110158972A1 (en) 2011-06-30
AU2012200863A1 (en) 2012-03-08
CN105999244A (zh) 2016-10-12
EP1987141A2 (en) 2008-11-05
JP6230200B2 (ja) 2017-11-15
JP2015128447A (ja) 2015-07-16
ES2709202T3 (es) 2019-04-15
US20110189153A1 (en) 2011-08-04
IL192878A0 (en) 2009-02-11
EP1987141B1 (en) 2018-12-05
US20110243919A1 (en) 2011-10-06
CN105999244B (zh) 2022-01-11
US20100233151A1 (en) 2010-09-16
IL291175B1 (en) 2023-10-01
US7811560B2 (en) 2010-10-12
IL254184A0 (en) 2017-10-31
US20110243908A1 (en) 2011-10-06
WO2007089851A3 (en) 2008-01-03
JP6792596B2 (ja) 2020-11-25
JP6851943B2 (ja) 2021-03-31
JP2012070758A (ja) 2012-04-12
IL192878A (en) 2013-03-24
DK1987141T3 (en) 2019-03-25
EP2474321B1 (en) 2019-04-17
PT2474321T (pt) 2019-07-25
KR20110046537A (ko) 2011-05-04
IL264361A (en) 2019-02-28
US20230158127A1 (en) 2023-05-25
KR20080093142A (ko) 2008-10-20
TR201903008T4 (tr) 2019-03-21
IL264361B (en) 2020-09-30
BRPI0708017A2 (pt) 2011-05-17
ES2992881T3 (en) 2024-12-19
WO2007089851A2 (en) 2007-08-09
DK2474321T3 (da) 2019-06-03
JP2017218452A (ja) 2017-12-14
US20160000889A1 (en) 2016-01-07
JP2021113212A (ja) 2021-08-05
NZ593907A (en) 2013-02-22
NZ569882A (en) 2012-03-30
US20240299508A1 (en) 2024-09-12
US20100330065A1 (en) 2010-12-30
CA2637262A1 (en) 2007-08-09
IL291175B2 (en) 2024-02-01
HUE044220T2 (hu) 2019-10-28
EP4483952A3 (en) 2025-04-02
JP6944989B2 (ja) 2021-10-06
JP2018143258A (ja) 2018-09-20
EP4483952A2 (en) 2025-01-01
JP2009525283A (ja) 2009-07-09
JP2017006143A (ja) 2017-01-12
PT1987141T (pt) 2019-03-04
US20110243920A1 (en) 2011-10-06
AU2012200863B2 (en) 2014-08-28
US20070224183A1 (en) 2007-09-27
AU2007211313B2 (en) 2011-12-01
HUE041764T2 (hu) 2019-05-28
CN101400788A (zh) 2009-04-01
AU2007211313C1 (en) 2014-05-22
EP3508571A1 (en) 2019-07-10
AU2007211313A1 (en) 2007-08-09
US20170087229A1 (en) 2017-03-30
US20210106659A1 (en) 2021-04-15
JP6389493B2 (ja) 2018-09-12
IL277322B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CA2637262C (en) Compositions and methods for treating collagen-mediated diseases
HK40122399A (en) Compositions suitable for treating collagen-mediated diseases
HK40011456B (en) Compositions suitable for treating collagen-mediated diseases
HK1125400B (en) Compositions suitable for treating collagen-mediated diseases
HK40011456A (en) Compositions suitable for treating collagen-mediated diseases

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241210

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209